GlassScriptPhysician profile
Robyn S Aydelott
NPI 1083041032
$3,856.20
in general payments reported to CMS, 2019-2025
25 companies · $635 in 2025
The $635 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $653 · 2022: $565 · 2023: $857 · 2024: $1,146 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,637.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $471.11 | 2021-2024 | |
| Abbott Laboratories | $426.28 | 2021-2024 | Cardiomems, Mitraclip, Freestyle Libre 2 |
| Actelion Pharmaceuticals US, INC. | $324.97 | 2023-2024 | Opsumit, Uptravi |
| Amgen INC. | $238.84 | 2024-2025 | Krystexxa |
| Boston Scientific Corporation | $227.94 | 2023-2025 | Watchman Access System |
| Novo Nordisk INC | $227.20 | 2022-2024 | Wegovy |
| Abiomed | $200.09 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $190.59 | 2024-2025 | Airsupra, Lokelma |
| Biohaven Pharmaceuticals, INC. | $172.12 | 2021 | |
| Nevro Corp. | $138.74 | 2021 | |
| Electronic Waveform Lab, INC. | $135.14 | 2021-2022 | |
| Corcept Therapeutics | $123.92 | 2025 | Korlym |
| Axonics, INC. | $118.04 | 2024 | Axonics, Bulkamid |
| Glaxosmithkline, LLC. | $112.15 | 2023 | |
| Insmed, INC. | $105.88 | 2025 | Arikayce |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $103.22 | 2023 | Quviviq |
| Gilead Sciences, INC. | $102.66 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.18 | 2024 | Jardiance |
| Lucid Diagnostics INC. | $100.43 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.50 | 2023 | |
| Collegium Pharmaceutical, INC. | $56.32 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $23.61 | 2021 | |
| Eisai INC. | $21.22 | 2021 | |
| Allergan, INC. | $19.16 | 2021 | |
| Scilex Pharmaceuticals INC. | $18.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Aydelott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.